Temozolomide in resistant or relapsed pediatric solid tumors

Pediatric Blood and Cancer

Volumn 47, Issue 1, 2006, Pages 30-36

  De Sio, L ^a   Milano, G M ^a   Castellano, A ^a   Jenkner, A ^a   Fidani, P ^a   Dominici, C ^a,b   Donfrancesco, A ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chemotherapy; Pediatric oncology; Solid; Tumors

Indexed keywords

NITROSOUREA DERIVATIVE; TEMOZOLOMIDE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG RESPONSE; DRUG TOLERABILITY; EPENDYMOMA; EWING SARCOMA; FEMALE; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MONOTHERAPY; NAUSEA; NEUROBLASTOMA; NEUROECTODERM TUMOR; OFF LABEL DRUG USE; OSTEOSARCOMA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RHABDOMYOSARCOMA; SKULL IRRADIATION; SOLID TUMOR; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; SURVIVAL ANALYSIS;

EID: 33646882667     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20516     Document Type: Article

References (19)

1. D'Atri S, Tentori L, Tricarico M, et al. Effects of triazenes on immune responses. In: Giraldi T, Connors TA, Carter G, editors. Triazene: Chemical, biological, and clinical aspects. New York, NY: Plenum Press; 1990. pp 63-77.
2. Tentori L, Leonetti C, Aquino A. Temozolomide reduces the metastatic potential of Lewis Lung Carcinoma (3LL) in mice: Role of a α-6-integrin phosphorylation. Eur J Cancer 1995;31:746-754.
3. Hochster H, Levin M, Speyer J. Single-dose dacarbazine and dactinomycin in advanced malignant melanoma. Cancer Treat Rep 1985;69:39-42.
4. 6-alkylguanine-DNA alkyltransferase deficient leukemic cell lines. Leukemia 1995;9:1888-1895.
5. Tsang LLH, Quarterman CP, Gescher A, et al. Comparison of the cytotoxicity of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1- yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol 1991;27:342-346.
6. Baer JC, Freeman AA, Newlands ES, et al. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 1993;67:1299-1302.
7. Wedge SR, Porteous JK, Newlands ES. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 1996; 74:1030-1036.
8. Nicholson HS, Krailo M, Ames MM, et al. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: A report from the Children's Cancer Group. J Clin Oncol 1998;16:3037-3043.
9. Newlands ES, Blackledge GRP, Slack JA, et al. Phase 1 trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992;65:287-291.
10. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas in childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 2002;20:4684-4691.
11. Glioma Meta-analysis Trialist (GMT). Chemotherapy in adult high grade glioma: A systematic review and meta-analysis of individual patients data from 12 randomised trials. Lancet 2002;359:1011-1018.
12. Osoba D, Brada M, Yung WKA, et al. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 2000;36:1788-1795.
13. Osoba D, Brada M, Prados MD, et al. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuroncology 2000;2:221-228.
14. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003;16:646-651.
15. Estlin EJ, Lashford L, Ablett S, et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer 1998; 78:652-661.
16. Hammond LA, Eckardt JR, Baker SD, et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999;8: 2604-2613.
17. Khan RB, Raizer JJ, Malkin MG. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuroncology 2002;4:39-43.
18. Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-593.
19. Jaekle KA, Hess KR, Yung WKA, et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent or progressive malignant glioma: A North-American Brain Tumor Consortium study. J Clin Oncol 2003;15:2305-2311.